ArticleCell communication and signaling : CCS2026
UNC5B activates hepatic stellate cells and promotes liver fibrosis via FAK.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundLiver fibrosis represents a critical stage in the progression of chronic liver diseases toward cirrhosis and hepatocellular carcinoma. However, there are no targeted therapies specifically designed for the treatment of liver fibrosis. This research aims to identify novel targets for anti-hepatic fibrosis and to provide new insights into therapeutic strategies for addressing this condition.
methodsDual-luciferase reporter assays and chromatin immunoprecipitation (ChIP) analyses were conducted to assess the modulation of UNC5B gene transcription. Co-immunoprecipitation experiments were performed to investigate the interactions between UNC5B and Src homology phosphotyrosyl phosphatase 2 (SHP2) or Focal adhesion kinase (FAK) proteins. Virtual screening was utilized to identify small-molecule inhibitors of UNC5B. The in vivo effects of Unc5b knockdown in liver fibrosis mouse models were evaluated using an Unc5b inhibitor (D359-0264) and an adeno-associated virus vector of serotype 6 (AAV6) containing short hairpin RNA targeting Unc5b.
resultsThis study demonstrates that the pro-fibrotic pathway TGF-β1/SMAD3 transcriptionally regulates UNC5B expression. Unc5b expression was significantly upregulated in liver fibrosis mouse models. Knocking down Unc5b resulted in reduced hepatocyte damage and decreased fibrosis in these models. Additionally, UNC5B was shown to interact with the PTP domain of SHP2 and the Y397 site of FAK, indicating that UNC5B competitively binds to the Y397 site of FAK, thereby inhibiting FAK dephosphorylation by SHP2 and promoting liver fibrosis.
conclusionThis study identifies a novel regulatory axis in liver fibrosis models involving UNC5B, which is regulated by the TGF-β/SMAD signaling pathway. UNC5B facilitates liver fibrosis by competitively binding to the Y397 site of FAK with SHP2, thus enhancing its phosphorylation and activating FAK. Furthermore, the UNC5B inhibitor has demonstrated the therapeutic potential of targeting this molecule for the treatment of liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.